Atossa Therapeutics Inc
ATOS0.830USD
+0.007+0.80%
交易中 （美東）報價延遲15分鐘
107.16M總市值
虧損本益比TTM
關於 Atossa Therapeutics Inc 公司
Atossa Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發腫瘤學領域尚未滿足的重大醫療需求領域的藥物，重點是使用 (Z)-endoxifen 預防和治療乳腺癌。該公司正在開發的主要候選藥物是口服 (Z)-endoxifen，用於預防和治療乳腺癌。(Z)-endoxifen 是一種強效的選擇性雌激素受體調節劑，可抑制雌激素受體並導致雌激素受體降解。除了其強效的抗雌激素作用外，(Z)-endoxifen 還被證明可以在臨牀可達到的血液濃度下靶向已知的致癌蛋白 PKCB1。該公司正在開發一種口服的 (Z)-endoxifen 形式，用於治療乳腺癌和降低乳腺密度。該公司已完成其專有的 (Z)-endoxifen（包括口服和外用製劑）的四項 I 期臨牀研究和兩項 II 期臨牀研究。
公司簡介
公司代碼ATOS
公司名稱Atossa Therapeutics Inc
上市日期Nov 08, 2012
CEODr. Steven C. (Steve) Quay, M.D., Ph.D.
員工數量13
證券類型Ordinary Share
年結日Nov 08
公司地址10202 5Th Avenue Ne
城市SEATTLE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編98125
電話12065880256
網址https://atossatherapeutics.com/
公司代碼ATOS
上市日期Nov 08, 2012
CEODr. Steven C. (Steve) Quay, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.15K
+45.11%
Dr. Shu-Chih Chen, Ph.D.
Dr. Shu-Chih Chen, Ph.D.
Director
Director
22.25K
--
Dr. Stephen J. Galli, M.D.
Dr. Stephen J. Galli, M.D.
Independent Director
Independent Director
99.00
--
Dr. Tessa Cigler, M.D.
Dr. Tessa Cigler, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan F. Finn
Mr. Jonathan F. Finn
Independent Director
Independent Director
--
--
Mr. H. Lawrence Remmel, Esq., J.D.
Mr. H. Lawrence Remmel, Esq., J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
--
--
Ms. Heather Rees, CPA
Ms. Heather Rees, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Parks
Mr. Michael Parks
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.15K
+45.11%
Dr. Shu-Chih Chen, Ph.D.
Dr. Shu-Chih Chen, Ph.D.
Director
Director
22.25K
--
Dr. Stephen J. Galli, M.D.
Dr. Stephen J. Galli, M.D.
Independent Director
Independent Director
99.00
--
Dr. Tessa Cigler, M.D.
Dr. Tessa Cigler, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan F. Finn
Mr. Jonathan F. Finn
Independent Director
Independent Director
--
--
Mr. H. Lawrence Remmel, Esq., J.D.
Mr. H. Lawrence Remmel, Esq., J.D.
Lead Independent Director
Lead Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.70%
The Vanguard Group, Inc.
4.52%
Heights Capital Management, Inc.
4.38%
Geode Capital Management, L.L.C.
2.20%
Columbia Threadneedle Investments (US)
2.00%
Other
80.19%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.70%
The Vanguard Group, Inc.
4.52%
Heights Capital Management, Inc.
4.38%
Geode Capital Management, L.L.C.
2.20%
Columbia Threadneedle Investments (US)
2.00%
Other
80.19%
股東類型
持股股東
佔比
Investment Advisor
17.75%
Investment Advisor/Hedge Fund
5.93%
Hedge Fund
1.60%
Research Firm
0.63%
Bank and Trust
0.11%
Individual Investor
0.07%
Pension Fund
0.02%
Other
73.89%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
165
36.31M
28.11%
-5.30M
2025Q1
171
34.47M
26.69%
-7.71M
2024Q4
167
36.07M
28.67%
-3.59M
2024Q3
170
35.56M
28.29%
+4.15M
2024Q2
166
34.42M
27.39%
+12.85M
2024Q1
166
27.40M
21.83%
+6.49M
2023Q4
166
16.33M
13.03%
-5.47M
2023Q3
184
24.37M
19.38%
-1.84M
2023Q2
197
24.20M
19.13%
-3.27M
2023Q1
206
24.64M
19.46%
-4.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.66M
6.7%
-132.60K
-1.51%
Mar 31, 2025
The Vanguard Group, Inc.
6.59M
5.1%
-33.06K
-0.50%
Mar 31, 2025
Heights Capital Management, Inc.
5.66M
4.38%
-2.10M
-27.05%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.85M
2.2%
+31.61K
+1.12%
Mar 31, 2025
Renaissance Technologies LLC
1.86M
1.44%
+297.47K
+19.10%
Mar 31, 2025
State Street Global Advisors (US)
1.73M
1.34%
-28.28K
-1.61%
Mar 31, 2025
Northern Trust Investments, Inc.
953.88K
0.74%
-71.25K
-6.95%
Mar 31, 2025
BlackRock Financial Management, Inc.
581.43K
0.45%
-2.34K
-0.40%
Mar 31, 2025
Squarepoint Capital LLP
479.00K
0.37%
+479.00K
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
